Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydrogen sulfide inhibits human platelet aggregation.

Giovanni Zagli1, Riccardo Patacchini, Marcello Trevisani

  • 1Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy. giovanni.zagli@unifi.it

European Journal of Pharmacology
|February 13, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Choice-Extracorporeal life support for out-of-hospital cardiac arrest: Part of a treatment bundle.

European heart journal. Acute cardiovascular care·2015
Same author

Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience.

Internal and emergency medicine·2015
Same author

Stereotactic body radiotherapy with CyberKnife for cardiac malignancies.

Tumori·2015
Same author

Characterization and identification of hidden rare variants in the human genome.

BMC genomics·2015
Same author

Early glucose variability in cardiogenic shock following acute myocardial infarction: a pilot study.

Therapeutic advances in cardiovascular disease·2015
Same author

Long-term prognostic role of uric acid in patients with ST-elevation myocardial infarction and renal dysfunction.

Journal of cardiovascular medicine (Hagerstown, Md.)·2015

Hydrogen sulfide (H2S) significantly inhibits human platelet aggregation induced by various agonists. This newly recognized mediator

Area of Science:

  • Cardiovascular physiology
  • Biochemistry
  • Endocrinology

Background:

  • Gaseous mediators like nitric oxide (NO) are crucial for cardiovascular homeostasis.
  • Platelet aggregation is a key process in cardiovascular function and thrombosis.

Purpose of the Study:

  • To investigate the effect of hydrogen sulfide (H2S) on human platelet aggregation.
  • To explore the mechanisms underlying H2S-mediated effects on platelets.

Main Methods:

  • Sodium hydrogen sulfide (NaHS) was used as an H2S donor.
  • Platelet aggregation was induced by various agonists, including ADP, collagen, epinephrine, arachidonic acid, U46619, and thrombin.
  • Platelet viability and signaling pathways (cAMP/cGMP, NO, potassium channels) were assessed.

Related Experiment Videos

Main Results:

  • NaHS demonstrated potent inhibition of platelet aggregation across multiple induction pathways.
  • H2S-induced inhibition was independent of cAMP/cGMP generation, NO production, or potassium channel activity.
  • H2S did not exhibit toxic effects on platelet viability at tested concentrations (up to 10 mM).

Conclusions:

  • Hydrogen sulfide (H2S) is a novel inhibitor of human platelet aggregation.
  • H2S may play a protective role in the cardiovascular system by modulating platelet function.
  • Further research is warranted to elucidate the therapeutic potential of H2S in cardiovascular diseases.